Literature DB >> 14871280

Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure.

V De Francesco1, A Zullo, M Margiotta, S Marangi, O Burattini, P Berloco, F Russo, M Barone, A Di Leo, M F Minenna, V Stoppino, S Morini, C Panella, A Francavilla, E Ierardi.   

Abstract

BACKGROUND: Predicting factors for the outcome of conventional Helicobacter pylori triple therapy have been identified. Of these, the presence of the CagA gene is a strong predictor of successful treatment. Our preliminary data show that this factor becomes irrelevant when sequential therapy is used. AIM: To identify predicting factors for the outcome of H. pylori eradication using two therapeutic schemes (triple and sequential) of equal duration (10 days).
METHODS: Ninety-six patients with H. pylori infection were randomly assigned to receive one of the following therapeutic schemes: group A: rabeprazole (20 mg b.d.) plus amoxicillin (1 g b.d.) for 5 days, followed by rabeprazole (20 mg b.d.) plus tinidazole (500 mg b.d.) and clarithromycin (500 mg b.d.) for a further 5 days; group B: rabeprazole (20 mg b.d.) plus amoxicillin (1 g b.d.) and clarithromycin (500 mg b.d.) for 10 days. Age, sex, smoking, endoscopic and histological findings, and CagA and VacA status were considered as candidates for a model of multivariate analysis which used therapeutic outcome as the dependent variable. CagA and VacA status were assessed by polymerase chain reaction on DNA isolated from gastric antral specimens.
RESULTS: The sequential scheme was significantly more effective than prolonged triple therapy (P < 0.05). Smoking (P < 0.001) and the absence of the CagA gene (P < 0.05) were significantly associated with the failure of triple therapy, but the effectiveness of sequential treatment was not predicted by these factors.
CONCLUSION: Our data suggest that sequential therapy is not affected by bacterial and host factors which have, until now, predicted the outcome of conventional eradication treatments.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14871280     DOI: 10.1046/j.1365-2036.2004.01818.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  24 in total

1.  Sequential Therapy for Helicobacter Pylori Eradication: The Time is Now!

Authors:  Dino Vaira; Angelo Zullo; Cesare Hassan; Giulia Fiorini; Nimish Vakil
Journal:  Therap Adv Gastroenterol       Date:  2009-11       Impact factor: 4.409

2.  Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report.

Authors:  P Malfertheiner; F Megraud; C O'Morain; F Bazzoli; E El-Omar; D Graham; R Hunt; T Rokkas; N Vakil; E J Kuipers
Journal:  Gut       Date:  2006-12-14       Impact factor: 23.059

3.  Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication.

Authors:  Xiao-Zhong Gao; Xiu-Li Qiao; Wen-Chong Song; Xiao-Feng Wang; Feng Liu
Journal:  World J Gastroenterol       Date:  2010-09-14       Impact factor: 5.742

4.  Role of gastritis pattern on Helicobacter pylori eradication.

Authors:  Angelo Zullo; Carola Severi; Lucy Vannella; Cesare Hassan; Andrea Sbrozzi-Vanni; Bruno Annibale
Journal:  Intern Emerg Med       Date:  2011-11-22       Impact factor: 3.397

5.  Association of helicobacter pylori dupA with the failure of primary eradication.

Authors:  Seiji Shiota; Lam Tung Nguyen; Kazunari Murakami; Akiko Kuroda; Kazuhiro Mizukami; Tadayoshi Okimoto; Masaaki Kodama; Toshio Fujioka; Yoshio Yamaoka
Journal:  J Clin Gastroenterol       Date:  2012-04       Impact factor: 3.062

6.  Sequential therapy versus standard triple therapy in Helicobacter pylori eradication in a high clarithromycin resistance setting.

Authors:  Can Dolapcioglu; Aysun Koc-Yesiltoprak; Emel Ahishali; Aziz Kural; Hatice Dolapcioglu; Aliye Soylu; Resat Dabak
Journal:  Int J Clin Exp Med       Date:  2014-08-15

Review 7.  Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy.

Authors:  Mitsushige Sugimoto; Yoshio Yamaoka
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2009-02-14       Impact factor: 4.291

Review 8.  How antibiotic resistances could change Helicobacter pylori treatment: A matter of geography?

Authors:  Enzo Ierardi; Floriana Giorgio; Giuseppe Losurdo; Alfredo Di Leo; Mariabeatrice Principi
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

9.  Helicobacter pylori therapy: Present and future.

Authors:  Vincenzo De Francesco; Enzo Ierardi; Cesare Hassan; Angelo Zullo
Journal:  World J Gastrointest Pharmacol Ther       Date:  2012-08-06

10.  Helicobacter pylori eradication with either 7-day or 10-day triple therapies, and with a 10-day sequential regimen.

Authors:  Giuseppe Scaccianoce; Cesare Hassan; Alba Panarese; Donato Piglionica; Sergio Morini; Angelo Zullo
Journal:  Can J Gastroenterol       Date:  2006-02       Impact factor: 3.522

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.